News | March 28, 2022
Tata Capital Healthcare Fund II raises Rs 955 crore
The fund will take equity positions in India-focused healthcare and life sciences-related companies
The fund will take equity positions in India-focused healthcare and life sciences-related companies
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Srichakra receives European Food Safety approval for its food-grade recycled rPET
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Price was the key driver for the period
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Subscribe To Our Newsletter & Stay Updated
